Koers AXIM Biotechnologies, Inc. Other OTC
Aandelen
AXIM
US05463V1008
Biotechnologie & Medisch Onderzoek
Omzet 2022 | 8,88K 8,17K | Omzet 2023 | 39,52K 36,37K | Marktkapitalisatie | 4,52 mln. 4,16 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2022 | -6 mln. -5,52 mln. | Nettowinst (verlies) 2023 | -8 mln. -7,36 mln. | EV/omzet 2022 | 1.218 x |
Nettoschuld 2022 | 5,64 mln. 5,19 mln. | Nettoschuld 2023 | 5,74 mln. 5,28 mln. | EV/omzet 2023 | 259 x |
K/w-verhouding 2022 |
-0,69
x | K/w-verhouding 2023 |
-0,48
x | Werknemers | - |
Dividendrendement 2022 * |
-
| Dividendrendement 2023 |
-
| Vrij verhandelbaar | 74,42% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
John Huemoeller
CEO | Chief Executive Officer | 68 | - |
Robert Malasek
DFI | Director of Finance/CFO | 55 | 29-06-16 |
Kurt Phinney
COO | Chief Operating Officer | - | 23-05-23 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
John Huemoeller
CEO | Chief Executive Officer | 68 | - |
Timothy Scott
BRD | Director/Board Member | 71 | 18-05-17 |
Director/Board Member | 76 | 18-05-17 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+41,79% | 54,04 mld. | |
+47,02% | 41,96 mld. | |
-0,56% | 41,92 mld. | |
-7,20% | 28,35 mld. | |
+12,59% | 26,35 mld. | |
-21,51% | 19 mld. | |
+6,92% | 13 mld. | |
+29,60% | 12,28 mld. | |
+24,91% | 12,19 mld. |